Login / Signup

Autoantibodies to Oxidatively Modified Peptide: Potential Clinical Application in Coronary Artery Disease.

I-Jung TsaiWen-Chi ShenJia-Zhen WuYu-Sheng ChangChing-Yu Lin
Published in: Diagnostics (Basel, Switzerland) (2022)
Coronary artery disease (CAD) is a global health issue. Lipid peroxidation produces various by-products that associate with CAD, such as 4-hydroxynonenal (HNE) and malondialdehyde (MDA). The autoantibodies against HNE and MDA-modified peptides may be useful in the diagnosis of CAD. This study included 41 healthy controls (HCs) and 159 CAD patients with stenosis rates of <30%, 30-70%, and >70%. The plasma level of autoantibodies against four different unmodified and HNE-modified peptides were measured in this study, including CFAH 1211-1230 , HPT 78-108 , IGKC 2-19 , and THRB 328-345 . Furthermore, feature ranking, feature selection, and machine learning models have been utilized to exploit the diagnostic performance. Also, we combined autoantibodies against MDA and HNE-modified peptides to improve the models' performance. The eXtreme Gradient Boosting (XGBoost) model received a sensitivity of 78.6% and a specificity of 90.4%. Our study demonstrated the combination of autoantibodies against oxidative modification may improve the model performance.
Keyphrases